[Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].

Wien Med Wochenschr 2008 ;158(3-4):98-109

Neurologische Abteilung, Krankenanstalt Rudolfstiftung, Wien, Australia.

During the last 10 years recombinant interferon-beta-1a administered subcutaneously has been the subject of several clinical trials in relapsing remitting multiple sclerosis (RRMS), in secondary progressive MS (SPMS), as well as in clinically isolated syndromes. All of them met the criteria of evidence level class I. Consistent evidence for moderate immunomodulatory effects on clinical parameters of disease activity was gained, and even higher efficacy of IFN-beta-1a sc. on MRI activity of multiple sclerosis was proven. Indirect evidence confirmed the hypothesis of a dose-response curve for IFN-beta-1a formulations in MS. The higher efficacy of IFN-beta-1a 44 microg sc. TIW, however, also includes more adverse events such as injection site reactions, flu-like symptoms and a moderate immunogenicity. Current evidence does not allow a recommendation of IFN-beta-1a sc. as most effective first line therapy, because also the individual patient's choice in the route of administration and long-term effects of neutralizing antibodies to IFN-beta-1a sc. must be taken into account. In the long-term, IFN-beta-1a showed a beneficial safety-tolerability profile with 50 % of patients sticking to the initial immunomodulatory treatment. There were no teratogenic effects, IFN-beta-1a sc. did not enhance depressive symptoms. Data on inhibition of the progression of disease, however, remained inconclusive. Probable beneficial effects of IFN-beta-1a sc. on cognitive function or "chronic fatigue" have not been investigated yet.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10354-008-0510-6DOI Listing
August 2009
1 Read

Publication Analysis

Top Keywords

effects ifn-beta-1a
8
higher efficacy
8
multiple sclerosis
8
ifn-beta-1a
8
efficacy ifn-beta-1a
8
symptoms moderate
4
moderate immunogenicity
4
flu-like symptoms
4
site reactions
4
injection site
4
immunogenicity current
4
reactions flu-like
4
evidence allow
4
effective therapy
4
therapy individual
4
individual patient's
4
ifn-beta-1a effective
4
recommendation ifn-beta-1a
4
events injection
4
allow recommendation
4

References

(Supplied by CrossRef)

A Compston et al.
Lancet 2002

SL Hauser et al.
Neuron 2006

LK Peterson et al.
J Neuroimmunol 2007

U Baumhackl et al.
Neuroepidemiology 2002

MS Freedman et al.
Expert Opin Pharmacother 2006

BG Weinshenker et al.
Brain 1989

WI Mc'Donald et al.
Ann Neurol 2001

PA Brex et al.
N Engl J Med 2002

AJ Wagstaff et al.
Bio Drugs 1998

M Chofflon et al.
Eur J Neurol 2000

A Munafo et al.
Eur J Neurol 1998

Similar Publications